



GOVERNMENT OF PAKISTAN
(CABINET DIVISION)
INTELLECTUAL PROPERTY ORGANIZATION
THE PATENT OFFICE
KARACHI



To,

Dated: 07-08-2009

Mr. Munir Ahmed,
Director (Admn.),
IPO-Pakistan,
Islamabad.

**Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 31-07-2009 TO BE PUBLISHED 10-08-2009 IN THE
GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No. 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL: Six pages.

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

27-07-2009

686/2009	Les Laboratoires Servier, France (Priority 05-08-2008 France)	“New process for obtaining the crystalline form V of agomelatine”
687/2009	Les Laboratoires Servier, France (Priority 05-08-2008 France)	“New process for the synthesis of agomelatine”
688/2009	Les Laboratoires Servier, France (Priority 05-08-2008 France)	“New process for the synthesis of agomelatine”
689/2009	Takeda Pharmaceutical Company Limited, Japan (Priority 28-07-2008 Japan)	“Pharmaceutical composition”
690/2009	Boehringer Ingelheim International GmbH., Germany	“Spirocyclic heterocycles, pharmaceutical compositions containing these compounds, and processes for preparing them”
691/2009	Boehringer Ingelheim International GmbH., Germany (Priority 29-07-2008 Europe)	“5-alkynyl-pyrimidines”
692/2009	Boehringer Ingelheim International GmbH., Germany (Priority 29-07-2008 Europe)	“New compounds”

28-07-2009

693/2009	Unilever Plc., United Kingdom (Priority 22-08-2008 India)	“Particulate filter”
----------	---	----------------------

694/2009	Tetra Laval Holdings & Finance S.A., Switzerland (Priority 09-08-2008 Europe)	“Software controlled package volume weight”
695/2009	BP Corporation North America Inc., USA (Priority 30-07-2008 USA)	“Minimal sour gas emission for an integrated gasification combined cycle complex”
696/2009	Basf SE Germany (Priority 30-07-2008 Europe)	“Insecticide-impregnated nets and their use for protection against pests”
697/2009	Merck, Co., Inc., USA (Priority 04-08-2008 USA)	“Oxazole derivatives useful as inhibitors of faah”

29-07-2009

698/2009	F. Hoffmann-La Roche AG., Switzerland (Priority 27-06-2000 Europe) Divisional	“A method for the preparation of pharmaceutical composition comprising 5-[7-[2-(5-methyl-2-phenyl-oxazole-4-yl)-ethoxy]-benzothiophene-4-methyl]-2,4-thiazolidinedione”
699/2009	Takeda Pharmaceutical Company Limited, Japan (Priority 31-07-2008 USA)	“Solid pharmaceutical composition”
700/2009	DyStar Textilfarben GmbH & Co. Deutschland KG., Germany (Priority 31-07-2008 Germany)	“Fiber-reactive azo dyes, preparation thereof and use thereof”

30-07-2009

701/2009	BP Alternative Energy International Limited. England (Priority 31-07-2008 Europe)	“Separation of carbon dioxide and hydrogen”
702/2009	Sanofi-Aventis, France (Priority 01-08-2008 France)	“Thiophene-2-carboxamide derivatives, their preparation and their therapeutic application”

703/2009	Blacklight Power, Inc., USA	“Heterogeneous hydrogen-catalyst reactor”
<u>31-07-2009</u>		
704/2009	Bayer CropScience AG, Germany (Priority 08-08-2008 Japan)	“Novel acylaminobenzamide derivatives”
705/2009	AstraZeneca AB, Sweden (Priority 04-08-2008 USA)	“Therapeutic agents 414”
706/2009	Tsui Hon Keung, China (Priority 05-08-2008 China)	“Multi function air-bubble plastic clothes and its manufacturing method”
707/2009	Eli Lilly and Company, USA (Priority 30-05-2007 USA) Divisional	A novel acetic acid salt of lactam cyclic peptide CXCR4 antagonist and its pharmaceutical composition comprising thereof”
708/2009	Merck, Co. Inc., USA (Priority 07-08-2008 USA)	“Tripyridyl carboxamide orexin receptor antagonists”
709/2009	Eli Lilly and Company, USA (Priority 21-04-2006 USA) Divisional	“A pharmaceutically acceptable salt of a substituted cyclohexylpyrazole-lactam compound”
710/2009	Celanese International Corporation, USA (Priority 31-07-2008 USA)	“Direct and selective production of ethanol from acetic acid utilizing a platinum/tin catalyst”
711/2009	Celanese International Corporation, USA (Priority 31-07-2008 USA)	“Direct and selective production of ethyl acetate from acetic acid utilizing a bimetal supported catalyst”
712/2009	Celanese International Corporation USA (Priority 31-07-2008 USA)	“Ethanol production from acetic acid utilizing a cobalt catalys”
713/2009	Celanese International Corporation, USA (Priority 31-07-2008 USA)	“Ethylene production from acetic acid utilizing dual reaction zone process”

714/2009	Celanese International Corporation, USA (Priority 31-07-2008 USA)	“Direct and selective production of acetaldehyde from acetic acid utilizing a supported metal catalyst”
715/2009	Celanese International Corporation, USA (Priority 31-07-2008 USA)	“Process for catalytically producing ethylene directly from acetic acid in a single reaction zone”

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.


The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

633/2004	LG Life Sciences Limited, Republic of Korea	“Substituted isoxazoline compound” CO7D 261/04
----------	--	---

140207

The present invention relates to an isoxazoline compound of the formula (I)



as an inhibitor against various caspases, and a therapeutic composition for preventing inflammation and apoptosis comprising the same.

340/2005	Bracker AG., Switzerland	“ A ring traveler for ring spinning or twisting machines”
----------	-----------------------------	---

DO1H 1/02, DO1H 7/00, DO1H 7/52

140208

The present invention relates to a ring traveler (10) for ring spinning or ring twisting machines,

with a core (20) consisting of a ferrous material, a covering layer (24) being arranged on at least parts of the core. The covering layer (24) in this case contains fine-crystalline chromium nitride, vanadium carbide or titanium carbonitride. As a result of the covering layer, the ring traveler according to the invention has good abrasion resistance and corrosion resistance.


805/2005 Sanofi-Aventis,
France

“Biotinylated hexadecasaccharide compound”

A61K 31/715, CO8B 37/00

140209

The present invention relates to novel biotinylated hexadecasaccharide of general formula I below:



in which:

- Biot is a biotin derivative;
- R, R₁ and R₂ represent, independently of each other, a (C₁-C₆)alkoxy or an -OSO₃⁻,
- R₃ represents a (C₁-C₆)alkoxy or an OSO₃⁻, or alternatively R₃ constitutes an -O-CH₂-bridge;
- Pe represents a saccharide chain;

1472/2007 ADC GmbH.,
Germany

“Plug-in connector for printed circuit boards”

HO1L 51/00, HO4N 7/26

140210

The invention relates to a plug-in connector (1) for printed circuit boards (40), comprising a number of contact elements (30), the contact elements (30) each having two connection side being in the form of a wire connection contact for connecting wires, and the other connection side being in the form of a fork contact (31) for making contact with connecting pads on a printed

circuit board (40), and a plastic housing, in which the contact elements (30) are arranged, it being possible for the wire connection contacts to be connected from the outside, the wire connection contacts being in the form of wire wrap contacts (32), which are arranged in at least two rows, the wire wrap contacts (32) of the different rows being arranged such that they are offset with respect to one another.

01/2008 Hesco Bastion
Limited,
England

“An improved gabion deployment system”

EO2D 29/02

140211

A gabion deployment system comprising: a container (30) for retaining a gabion (22) and a gabion (22) of the folding type comprising hingedly attached, connected side walls (16 & 18) and cross-members (12) such that it can be folded for storage and deployed for use; a retaining means (50) associated with the container (30) for retaining the gabion (20) in the container; and at least one releasable attaching, connecting or retentive engaging means (66) for attaching, connecting or retentively engaging at least one part of the gabion (22) to the retaining means (50); wherein the at least one releasable attaching, connecting or retentively engaging means (66) is adapted to attach, connect or retentively engage a part of the gabion (22) to the retaining means (50) when the gabion (22) is folded but to release the gabion (22) from the retaining means (50) when the gabion (22) is deployed.




Figure 5a

818/2008 LG Life Sciences
Limited,
Republic of Korea

“Process for the preparation of a substituted
isoxazoline compound”

CO7D 261/04

140212

The present invention relates to a process for the preparation of a compound (3S)-5-fluoro-3-({[(5R)-5-isopropyl-3-(1-isoquinolinyl)-4,5-dihydro-5-isoxazolyl]carbonyl}amino)-4-oxopentanoic acid (Iii-I) as an inhibitor against various caspases, and of a therapeutic composition for preventing inflammation and apoptosis comprising the same.

(MRS. YASMEEN ABBASI)
CONTROLLER OF PATENTS
Tel: 9215488